Daiichi Sankyo to acquire sales force

Daiichi Sankyo is set to acquire the primary care sales force for cardiometabolic products from Merck Serono.

Those looking for science sales jobs may be interested to hear more than 200 employees will be involved in the agreement between the two companies.

Daiichi Sankyo will as a result market products, including anti-hypertensive agent Cardensiel (Bisoprolol) and the diabetes therapy Stagid (Metformin).

The agreement is the fourth such deal reached between the two companies in 2008.

Reinhard Bauer, chief executive officer of Daiichi Sankyo Europe, said the company is now marketing "strong-selling, patented medications" in order to fight osteoporosis and hypertension in France.

"The acquisition of a well-organised, successful sales force with extensive experience in the cardiovascular diseases and metabolic products is an excellent way to meet the large need for additional employees," he added.

By 2015, the group says it intends to be one of Europe’s leading pharmaceutical companies.

Of Daiichi Sankyo’s consolidated turnover, 60 per cent is generated in Japan, however it is hoped 60 per cent will be achieved outside of the country by seven years’ time.

Earlier this month, the company announced results of three studies of its Oral Factor Xa inhibitor.